Neuromod Devices

Neuromod Devices has today announced the company has closed €10m financing to accelerate commercialisation, and availability of Lenire Tinnitus Treatment Device. Financing led by existing investors Fountain Healthcare Partners and Panakes Partners.

“We are delighted to announce an oversubscribed financing at a pivotal time when we are driving forward with our mission of making Neuromod the category creator for tinnitus globally,” said Dr. Ross O’Neill PhD, Founder & CEO of Neuromod.

Neuromod Devices | Neuromod Closes €10m Financing to Accelerate Commercialisation Neuromod Devices is an ambitious, forward-looking medical technology company formed to advance the science of neuromodulation, we named ourselves Neuromod in the shared belief of what this cutting edge branch of medicine can achieve.

Don't miss Session One of the The Tinnitus Collaborative's Virtual Sessions 2024, starting at 4PM (EST) on Tuesday, Oct. 22 — https://shorturl.at/jplWC

Dr. Craig Kasper Au. D. will discussing Bimodal Neuromodulation for Tinnitus: Real-World Clinical Outcomes of Lenire, and Dr. Rachael Cook, Au.D. will dive into Biometric Tracking & Personalized Care of Tinnitus Patients.

Register for The Tinnitus Collaborative Virtual Sessions: Session One for an exciting look at the future of tinnitus care with leading tinnitus experts.

"Expect bimodal neuromodulation to be one of the most popular forms of treatment..."

Check out Doctor Cliff AuD's video about the results of the TENT-A3 controlled clinical trial of Lenire Tinnitus Treatment Device.

TENT-A3's results were pivotal in Lenire becoming the first and only bimodal neuromodulation device approved for the treatment of tinnitus by the US FDA.

Dr. Olson discusses:
- How the TENT-A3 trial was designed and controlled
- The importance of evidence for tinnitus treatment
- The significance of Lenire's benefit for people living with tinnitus

Doctor Cliff AuD Educating consumers about hearing loss and treatment options.